Beta Bionics (NASDAQ:BBNX) Coverage Initiated by Analysts at Robert W. Baird

Robert W. Baird started coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research note released on Thursday morning, MarketBeat Ratings reports. The brokerage issued a neutral rating and a $20.00 target price on the stock.

Beta Bionics Price Performance

Shares of BBNX stock opened at $20.87 on Thursday. Beta Bionics has a 12 month low of $20.84 and a 12 month high of $24.50.

Insider Activity

In other Beta Bionics news, insider Mike Mensinger acquired 33,350 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $17.00 per share, with a total value of $566,950.00. Following the transaction, the insider now owns 59,019 shares of the company’s stock, valued at $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of Beta Bionics stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the acquisition, the insider now owns 3,901,599 shares in the company, valued at $66,327,183. This trade represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.